Market revenue in 2023 | USD 79.0 million |
Market revenue in 2030 | USD 223.3 million |
Growth rate | 16% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.94% in 2023. Horizon Databook has segmented the South Korea hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea's hereditary angioedema therapeutics market is expected to witness significant growth over the forecast period owing to various factors, including increasing healthcare expenditure, favorable government initiatives, and the growing prevalence of the condition in the country.
However, lack of awareness and availability of proper and effective therapeutics, such as the use of C1 inhibitor concentrates in the market, is hampering the overall growth in the country. For instance, Berinert was approved by the Korean Ministry of Drugs and Food Safety in 2011, and CSL Korea signed a contract to import Berinert on April 1, 2021, though it has yet to be imported.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into South Korea hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account